Clinical trials: Recurrent Metastases
Breast Cancer, Metastases
DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer
The purpose of this trial is to study DPPE combined with epirubicin and cyclophosphamide in patients with metastatic and/or recurrent breast cancer who may have received previous hormone treatment but have not had exposure to…
- Trial name
- NCT00099281
- Testing
- YMB 1002
- Where
- United Kingdom
- Volunteers
- 700 people
- Sponsor
- YM BioSciences
Brain Metastases
Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases
An open-label, single dose, single arm, prospective, multicenter Phase 3 study to establish the diagnostic performance of 18F fluciclovine positron emission tomography (PET) in detecting recurrent brain metastases after radiation…
- Trial name
- REVELATE (NCT04410133)
- Testing
- 18F fluciclovine
- Where
- 19 sites in United States
- Volunteers
- 151 people
- Sponsor
- Blue Earth Diagnostics
Solid Tumor
Exploratory Study on Baize DC Injection in Preventing Recurrence and Metastasis After Radical Tumor Surgery
This is an exploratory study on the safety, immune response, and preliminary effectiveness of single arm, fixed dose therapy
- Trial name
- NCT06015269
- Testing
- DC cells
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
Prostate Cancer
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival…
- Trial name
- EvoPAR-PR02 (NCT06952803)
- Testing
- Saruparib, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
- Where
- 346 sites in United States, Argentina and 26 more
- Volunteers
- 700 people
- Sponsor
- AstraZeneca
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- NEXUS-01 (NCT06465069)
- Testing
- LY4052031, Pembrolizumab
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Leukemia
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias
RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00098436
- Testing
- laromustine, temozolomide
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Vion Pharmaceuticals
Solid Tumors
Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors
The purpose of this study is to determine the tolerability of ME-143, find the maximum tolerated dose, and the safety profile in patients with refractory solid tumors.
- Trial name
- NCT01401868
- Testing
- ME-143
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- MEI Pharma, Inc.
Head and Neck Squamous Cell Carcinoma, Skin Cancer
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
A unique combinational treatment for cancer employing intratumoral diffusing alpha radiation emitter device with check point inhibitor for recurrent unresectable or metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma
- Trial name
- NCT05047094
- Testing
- Diffusing Alpha Radiation Emitters Therapy (DaRT), Pembrolizumab
- Where
- 3 sites in Israel
- Volunteers
- 48 people
- Sponsor
- Alpha Tau Medical LTD.
Graft Versus Host Disease, Leukemia
Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation
RATIONALE: Bone marrow that has been treated to remove certain white blood cells may reduce the chance of developing graft-versus-host disease following bone marrow transplantation.
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00004255
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- 15 sites in United States
- Sponsor
- Chimeric Therapies
Metastatic Renal Cell Carcinoma, Metastatic Clear-cell Renal Cancer
Immunotherapy Study for Metastatic Renal Cell Cancer
In this Phase 1 Trial investigators plan to establish the MTD of HyperAcute®-Renal (HAR) immunotherapy in subjects with clinically metastatic renal cell carcinoma.
- Conditions
- Metastatic Renal Cell Carcinoma, Metastatic Clear-cell Renal Cancer, Recurrent Renal Cell Carcinoma, Refractory Renal Cell Carcinoma
- Trial name
- NCT02035358
- Testing
- HyperAcute®-Renal (HAR) Immunotherapy
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- NewLink Genetics Corporation
HPV 16+ Recurrent or Metastatic Cancer, HNSCC
Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors
This is a phase I, open-label, dose escalation study to assess the safety, tolerability, efficacy and immunogenicity of TI-0093 injection in patients with recurrent or metastatic HPV-16 positive solid tumors.
- Conditions
- HPV 16+ Recurrent or Metastatic Cancer, HNSCC, Cervical Cancer
- Trial name
- NCT07081984
- Testing
- therapeutic tumor vaccine
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Therorna
Carcinoma, Squamous Cell of the Head and Neck
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
The purpose of this Phase 3 study is to evaluate overall survival and progression free survival following intravenous administration of REOLYSIN (Reovirus Serotype 3 Dearing) in combination with paclitaxel and carboplatin versus…
- Trial name
- NCT01166542
- Testing
- REOLYSIN, Carboplatin, Paclitaxel
- Where
- 77 sites in United States, Belgium and 11 more
- Volunteers
- 167 people
- Sponsor
- Oncolytics Biotech
Astrocytoma, Grade IV, Giant Cell Glioblastoma
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
This study will find the maximum safe dose (MSD) or maximum tolerated dose (MTD) of CYNK-001 which are NK cells derived from human placental CD34+ cells and culture-expanded.
- Conditions
- Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Cyclophosphamide
- Trial name
- CYNK001GBM01 (NCT04489420)
- Testing
- CYNK001-IV, CYNK001-IT
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Celularity Incorporated
Advanced Cancer
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine…
- Trial name
- NCT05270213
- Testing
- RBS2418, Pembrolizumab, Other approved anti-cancer therapy
- Where
- 14 sites in United States
- Volunteers
- 164 people
- Sponsor
- Riboscience, LLC.
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate LYL845 in Adults With Solid Tumors
This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT05573035
- Testing
- LYL845
- Where
- 18 sites in United States
- Volunteers
- 39 people
- Sponsor
- Lyell Immunopharma, Inc.
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04540588
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
Differentiated Thyroid Carcinoma (DTC)
Post-Marketing Surveillance of Lenvima in Korean Patients
The purpose of this post-marketing surveillance (PMS) is to observe the safety profile of Lenvima (lenvatinib) in normal clinical practice setting.
- Trial name
- NCT02764554
- Where
- 32 sites in South Korea
- Volunteers
- 132 people
- Sponsor
- Eisai Korea Inc.
Leukemia
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them…
- Trial name
- NCT00006045
- Testing
- lintuzumab, cytarabine, etoposide
- Where
- 59 sites in United States, Belgium and 5 more
- Sponsor
- Facet Biotech
Brain and Central Nervous System Tumors, Neuroblastoma
Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
The purpose of this study is to test the feasibility and toxicity of administering intrathecal immunotherapy for patients with central nervous system/leptomeningeal (CNS/LM) malignancies.
- Conditions
- Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
- Trial name
- NCT00089245
- Testing
- Iodine I 131 MOAB 8H9
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- Y-mAbs Therapeutics
Neoplasms, Breast Neoplasms
Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)
The main purpose of this study is to determine if AZD8931 can improve the efficacy of standard chemotherapy for the treatment of advanced breast cancer.
- Conditions
- Neoplasms, Breast Neoplasms, Breast Cancer
- Trial name
- THYME (NCT00900627)
- Testing
- AZD8931, Paclitaxel
- Where
- 38 sites in Belgium, Brazil and 12 more
- Volunteers
- 330 people
- Sponsor
- AstraZeneca